89 204

Cited 7 times in

Efficacy of Tandem High-Dose Chemotherapy and Autologous Stem Cell Rescue in Patients Over 1 Year of Age with Stage 4 Neuroblastoma: The Korean Society of Pediatric Hematology-Oncology Experience Over 6 Years (2000-2005).

 Ki Woong Sung  ;  Hyo Seop Ahn  ;  Bin Cho  ;  Yong-Mook Choi  ;  Nack Gyun Chung  ;  Tai Ju Hwang  ;  Ho Joon Im  ;  Dae Chul Jeong  ;  Hyoung Jin Kang  ;  Hong Hoe Koo  ;  Hoon Kook  ;  Hack Ki Kim  ;  Chuhl Joo Lyu  ;  Jong Jin Seo  ;  Hee Young Shin  ;  Keon Hee Yoo  ;  Sung Chul Won  ;  Kun Soo Lee 
 JOURNAL OF KOREAN MEDICAL SCIENCE, Vol.25(5) : 691-697, 2010 
Journal Title
Issue Date
Adolescent ; Child ; Child, Preschool ; Combined Modality Therapy/mortality ; Drug Therapy/mortality* ; Female ; Humans ; Infant ; Korea/epidemiology ; Longitudinal Studies ; Male ; Neuroblastoma/mortality* ; Neuroblastoma/therapy* ; Prevalence ; Risk Assessment/methods ; Risk Factors ; Stem Cell Transplantation/mortality* ; Survival Analysis ; Survival Rate ; Treatment Outcome
Neuroblastoma ; High-dose Chemotherapy ; Transplantation ; Autologous
The efficacy of tandem high-dose chemotherapy and autologous stem cell rescue (HDCT/ASCR) was investigated in patients with high-risk neuroblastoma. Patients over 1 yr of age who were newly diagnosed with stage 4 neuroblastoma from January 2000 to December 2005 were enrolled in The Korean Society of Pediatric Hematology-Oncology registry. All patients who were assigned to receive HDCT/ASCR at diagnosis were retrospectively analyzed to investigate the efficacy of single or tandem HDCT/ASCR. Seventy and 71 patients were assigned to receive single or tandem HDCT/ASCR at diagnosis. Fifty-seven and 59 patients in the single or tandem HDCT group underwent single or tandem HDCT/ASCR as scheduled. Twenty-four and 38 patients in the single or tandem HDCT group remained event free with a median follow-up of 56 (24-88) months. When the survival rate was analyzed according to intent-to-treat at diagnosis, the probability of the 5-yr event-free survival+/-95% confidence intervals was higher in the tandem HDCT group than in the single HDCT group (51.2+/-12.4% vs. 31.3+/-11.5%, P=0.030). The results of the present study demonstrate that the tandem HDCT/ASCR strategy is significantly better than the single HDCT/ASCR strategy for improved survival in the treatment of high-risk neuroblastoma patients
Files in This Item:
T201005337.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아청소년과학교실) > 1. Journal Papers
Yonsei Authors
Won, Sung Chul(원성철)
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.